Skip to main content
Year archive

Swedish Orphan Biovitrum — 2016 filings

All 47 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2016, sourced directly from the official regulator.

47 Filings
2016 Period
2016 filings (47)
Filing Released Lang
Interim / Quarterly Report 2016
Interim / Quarterly Report Q3 2016
2016-10-27 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Q3 2016
2016-10-27 English
Milan Zdravkovic joins Sobi as Senior Vice President, Head of Research & Development
Board/Management Information
2016-09-26 English
Milan Zdravkovic blir Senior Vice President, Head of Research & Development på Sobi
Board/Management Information
2016-09-26 Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2016-08-31 English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Share Issue/Capital Change
2016-08-31 Swedish
Sobis vd avyttrar del av aktier
Director's Dealing
2016-08-08 Swedish
Sobi’s CEO divests a portion of shares
Director's Dealing
2016-08-08 English
Styrelsen för Sobi utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram
Transaction in Own Shares
2016-07-15 Swedish
Sobi's Board of directors exercises its authorisation for repurchase of shares to secure the company’s commitments under the incentive programme
Transaction in Own Shares
2016-07-15 English
Interim / Quarterly Report 2016
Interim / Quarterly Report Q2 2016
2016-07-15 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Q2 2016
2016-07-15 English
Sobi’s Elocta® (rFVIIIFc) approved in Switzerland for the treatment of haemophilia A
Regulatory Filings
2016-06-27 English
Sobis Elocta® (rFVIIIFc) godkänd i Schweiz för behandling av hemofili A
Regulatory Filings
2016-06-27 Swedish
Sobi tar upp ny kreditfacilitet och förtidslöser obligationslån 2012/2017 på 800 Mkr
Capital/Financing Update
2016-05-27 Swedish
Sobi enters new credit facility and redeems SEK 800 M bond loan 2012/2017 prior to final maturity
Capital/Financing Update
2016-05-27 English
Resolutions from Swedish Orphan Biovitrum AB’s (Sobi™) Annual General Meeting (AGM)
AGM Information
2016-05-24 English
Kommuniké från Swedish Orphan Biovitrum ABs (Sobi™)årsstämma
AGM Information
2016-05-24 Swedish
Sobis vd avyttrar del av incitamentsaktier
Remuneration Information
2016-05-16 Swedish
Sobi's CEO divests a portion of incentive shares
Director's Dealing
2016-05-16 English
Alprolix® (rFIXFc) godkänd i EU för behandling av hemofili B
Regulatory Filings
2016-05-13 Swedish
Alprolix® (rFIXFc) approved in the EU for the treatment of haemophilia B
Earnings Release FY 2016
2016-05-13 English
Swedish Orphan Biovitrum AB (publ): Bo Jesper Hansen sells 8 million shares
Board/Management Information
2016-05-04 English
Swedish Orphan Biovitrum AB (publ): Bo Jesper Hansen säljer 8 miljoner aktier
Board/Management Information
2016-05-04 Swedish
Sobi tecknar tillverkningsavtal med Pfizer
Regulatory Filings
2016-04-29 Swedish
Sobi signs manufacturing agreements with Pfizer
Regulatory Filings
2016-04-29 English
Annual Report 2015
Annual Report FY 2015
2016-04-27 Swedish
Annual Report 2015
Annual Report FY 2015
2016-04-27 English
Interim / Quarterly Report 2016
Interim / Quarterly Report Q1 2016
2016-04-27 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Q1 2016
2016-04-27 English
Sobi publishes its report for the first quarter 2016
Interim / Quarterly Report Q1 2016
2016-04-27 English
Sobi publicerar sin rapport för första kvartalet 2016
Interim / Quarterly Report Q1 2016
2016-04-27 Swedish
Rättelse av kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ) på grund av skrivfel i den svenska versionen av kallelsen
AGM Information
2016-04-22 Swedish
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information
2016-04-20 Swedish
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information
2016-04-20 English
European Commission approves transfer of marketing authorisation for Elocta® to Sobi
Regulatory Filings
2016-03-24 English
EU-kommissionen godkänner överföring av marknadsföringstillstånd för Elocta® till Sobi
Regulatory Filings
2016-03-24 Swedish
Sobi meddelar nytt datum för årsstämman
Report Publication Announcement
2016-03-08 Swedish
Sobi announces new date for Annual General Meeting of shareholders
Board/Management Information
2016-03-08 English
Sobi updates outlook for 2016
Earnings Release Q2 2016
2016-02-29 English
Sobi uppdaterar utsikterna för 2016
Earnings Release FY 2016
2016-02-29 Swedish
Sobi and Biogen receive positive opinion from CHMP for Alprolix® (rFIXFc) for the treatment of haemophilia B
Regulatory Filings
2016-02-26 English
Sobi och Biogen får CHMP-rekommendation för Alprolix® (rFIXFc) för behandling av hemofili B
Regulatory Filings
2016-02-26 Swedish
Interim / Quarterly Report 2015
Interim / Quarterly Report Q4 2015
2016-02-26 Swedish
Interim / Quarterly Report 2015
Interim / Quarterly Report FY 2015
2016-02-26 English
Chief Medical Officer Birgitte Volck lämnar Sobi
Board/Management Information
2016-01-14 Swedish
Chief Medical Officer Birgitte Volck to leave Sobi
Board/Management Information
2016-01-14 English